The broad anti-AML activity of the CD33/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Harrington, Kimberly H ^a   Gudgeon, Chelsea J ^a   Laszlo, George S ^a   Newhall, Kathryn J ^b   Sinclair, Angus M ^c   Frankel, Stanley R ^d   Kischel, Roman ^e   Chen, Guang ^b   Walter, Roland B ^a,f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b AMGEN INC   (United States)

^c AMGEN INC   (United States)

^d Amgen Inc   (United States)

^e Amgen Research GmbH   (Germany)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 330; ANTINEOPLASTIC AGENT; CD33 ANTIGEN; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD3 ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COLONY FORMING CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MONONUCLEAR CELL; MYELOBLAST; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; T LYMPHOCYTE; TARGET CELL; TUMOR CELL DESTRUCTION; VERY ELDERLY; BIOSYNTHESIS; CYTOTOXICITY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES;

EID: 84942919241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135945     Document Type: Article

References (33)

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011; 29(5):487-494. doi: 10.1200/JCO.2010.30.1820 PMID: 21220605
2. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013; 381(9865):484-495. doi: 10. 1016/S0140-6736(12)61727-9 PMID: 23399072
3. Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, et al. Declining rates of treatmentrelated mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014; 28(2):289-292. doi: 10.1038/leu.2013.176 PMID: 23760400
4. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012; 119(26):6198-6208. doi: 10.1182/blood-2011-11-325050 PMID: 22286199
5. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014; 28(4):143-153. doi: 10.1016/j.blre.2014.04.001 PMID: 24809231
6. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a metaanalysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014; 15(9):986-996. doi: 10.1016/S1470-2045(14)70281-5 PMID: 25008258
7. Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with De Novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2014; 32(27):3021-3032. PMID: 25092781
8. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005; 10(18):1237-1244. PMID: 16213416
9. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4944. doi: 10.1158/0008-5472.CAN-09-0547 PMID: 19509221
10. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther. 2011; 11(7):843-853. doi: 10.1517/14712598.2011. 572874 PMID: 21449821
11. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun. 2012; 12:12. PMID: 22896757
12. Wickramasinghe D. Tumor and T cell engagement by BiTE. Discov Med. 2013; 16(88):149-152. PMID: 24099669
13. Walter RB. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev Hematol. 2014; 7(3):317-319. doi: 10.1586/17474086.2014.896190 PMID: 24617311
14. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013; 27(5):1107-1115. doi: 10.1038/leu.2012.341 PMID: 23178753
15. Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG. Blood. 2014; 123(3):356-365. doi: 10.1182/blood-2013-08-523548 PMID: 24300852
16. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014; 123(4):554-561. doi: 10.1182/blood-2013-09-527044 PMID: 24311721
17. Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014; 13(6):1549-1557. doi: 10.1158/1535-7163.MCT-13-0956 PMID: 24674885
18. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-951. doi: 10.1182/blood-2009-03-209262 PMID: 19357394
19. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-365. doi: 10.1182/blood-2009-11-254441 PMID: 20385793
20. Walter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, et al. Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia. 2014; 28(10):1969-1977. doi: 10.1038/leu.2014.107 PMID: 24721792
21. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001; 1(2): 118-129. PMID: 11905803
22. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891):974-977. doi: 10. 1126/science.1158545 PMID: 18703743
23. Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in Blineage ALL. Blood. 2012; 120(26):5185-5187. doi: 10.1182/blood-2012-07-441030 PMID: 23024237
24. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36): 4134-4140. doi: 10.1200/JCO.2014.56.3247 PMID: 25385737
25. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16(1):57-66. doi: 10.1016/S1470-2045 (14)71170-2 PMID: 25524800
26. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004; 104(7):1940-1951. PMID: 15217827
27. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia. 2007; 21(6):1172-1176. PMID: 17429427
28. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012; 119(16):3705-3711. doi: 10.1182/blood-2011-12-398370 PMID: 22378848
29. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002; 118(4):560-566. PMID: 12375643
30. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia. 1989; 3(6):440-445. PMID: 2725060
31. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2007; 37(1):73-82. PMID: 17181570
32. De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011; 96(10):1548-1551. doi: 10.3324/haematol.2011.043786 PMID: 21791474
33. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013; 122(8):1455-1463. doi: 10.1182/blood-2013-03-491506 PMID: 23770776